Pephexia Therapeutics ApS: Financial statements 2021
CVR: 41319208
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Pephexia Therapeutics ApS (CVR 41319208) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 626,000 and a net result of DKK -4,532,328. The profit margin was -724%. Equity in the 2021 report amounted to DKK -2,652,069.
- Revenue
- DKK 626,000
- Gross Profit
- DKK -4,738,037
- Profit/Loss
- DKK -4,532,328
- Equity
- DKK -2,652,069
- Total Assets
- DKK 4,812,136
- Employees
- 0
Official annual report
Find more companies like Pephexia Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
Pephexia Therapeutics ApS has published its interim report for the period April 24, 2020 to December 31, 2020.
About Pephexia Therapeutics ApS
Pephexia Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Keld Fogtmann Fosgerau. The board consists of Anders Mørkeberg Hinsby (chair), Andrew Justin Stewart Coats, Keld Fogtmann Fosgerau and Mats Peter Blom. The company is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345.